Drug Trial Radar · NCT07831122
Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
108
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Jan 2033
Study completion Mar 2033
Sponsor
- Lead sponsor
- Canadian Myeloma Research GroupAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GlaxoSmithKline; Hoffmann-La Roche
- First posted
- Sep 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate efficacy and tolerability various doses of belantamab mafodotin in combination with cevostamab and pomalidomide in patients with multiple myeloma who have relapsed disease after two or more lines of therapy and/or have refractory to treatment disease.
Conditions
- Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
BelamafDrug
Administered intravenously
CevostamabBiological
Administered intravenously
PomalidomideDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Recommended Phase 2 Dose (RP2D)Time frame: From the first dose of study drugs until the end of 3 cycles of therapy (up to 9 weeks; each cycle is 21 days) in the last dose-escalation cohort, or until study therapy is discontinued due to disease progression or toxicity, whichever occurs first.
- Overall Response Rate (ORR)Time frame: From 3 weeks after the first dose of study therapy (end of Cycle 1; Cycle 1 is 21 days) until the date of documented disease progression or death from any cause, whichever occurs first, assessed up to 24 months.
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Cross Cancer Institute
Edmonton, Alberta, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
London Health Sciences Centre
London, Ontario, Canada
The Ottawa Hospital - General Hospital
Ottawa, Ontario, Canada
UHN-Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Hospital Maisonneuve - Rosemont
Montreal, Quebec, Canada
McGill University Health Centre -MUHC
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.